Salman Akhtar

3 weeks ago | abbonews.com | Salman Akhtar

Shares of Doximity (NYSE: DOCS) plunged about 22% in pre-market trading on Friday after the company issued weaker-than-expected revenue guidance for the first quarter and full fiscal year 2026. The sell-off came even as the digital platform for U.S. medical professionals reported better-than-expected fourth quarter results. For the fiscal fourth quarter, Doximity posted adjusted earnings per share of $0.38, well above Wall Street estimates of $0.27.

3 weeks ago | abbonews.com | Salman Akhtar

Shares of CoreWeave (NASDAQ: CRWV) plunged over 5% in pre-market trading on Thursday following the release of its first quarterly earnings report as a public company. While the cloud computing startup reported stronger-than-expected revenue, investor concerns over its high capital expenditure (CapEx) guidance weighed heavily on the stock.

3 weeks ago | abbonews.com | Salman Akhtar

Exelixis (NASDAQ: EXEL) shares jumped over 6% in pre-market trading on Wednesday after the company reported better-than-expected first-quarter results and lifted its full-year revenue outlook. The biopharmaceutical company posted adjusted earnings of $0.62 per share, well above the analysts’ consensus estimate of $0.37. Revenue for the quarter reached $555.4 million, beating estimates of $495.3 million and marking a 30.6% increase year-over-year.

3 weeks ago | abbonews.com | Salman Akhtar

UBS analysts expect Nvidia (NASDAQ: NVDA) to report fiscal first-quarter results slightly ahead of guidance, potentially easing investor concerns about short-term growth amid regulatory and supply chain challenges. In a preview note, UBS forecasts April-quarter revenue of approximately $44 billion, slightly ahead of the company’s guidance of $43 billion. However, adjusted earnings per share (EPS) are expected at $0.76, below the Street consensus of $0.89.

3 weeks ago | abbonews.com | Salman Akhtar

Shares of Novo Nordisk (NYSE: NVO) fell more than 3% in pre-market trading Monday after Eli Lilly’s Zepbound outperformed Wegovy in a head-to-head weight loss trial. In the 72-week SURMOUNT-5 trial, adults with obesity or overweight and at least one weight-related medical condition—excluding diabetes—achieved an average weight loss of 20.2% on Zepbound, compared to 13.7% on Wegovy. This translates to a 47% greater relative reduction in body weight for patients taking Zepbound.